Targets › HIF1A
2 programs from 2 companies in 5 trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Genitourinary, Hematology, Oncology; next expected readout Dec 2026.
Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. (UniProt, Q16665)
Open in Phaseline: the race on HIF1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kind Pharmaceuticals | AND017 HIF-1α stabilizer | HIF1A | Phase 3 | Anemia Due to Chronic Kidney Disease; Myelodysplastic Syndromes; β -Thalassemia | Dec 2026 |
| ImmunoGenesis | Evofosfamide Hypoxia-inducible factor 1-alpha (HIF-1α) inhibitor; prodrug activated under hypoxic condi | HIF1A | Phase 1 | Metastatic Prostate Cancer | Oct 2027 |
Anemia Due to Chronic Kidney Disease (2) Myelodysplastic Syndromes (1) β -Thalassemia (1) Metastatic Prostate Cancer (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.